Strong Proof-of-Concept for cross-strain protective flu cVLP vaccine further strengthens confidence in Coronavirus vaccine
Hørsholm, Denmark, July 17, 2020 – ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) announces that AdaptVac has announced publication of a paper in the journal Vaccines, where its broadly protective Flu cVLP vaccine induced a more potent, long-lasting immune response and was able to protect mice against both homologous and heterologous H1N1 influenza challenge, even after a single dose.
Dr. Wian de Jongh, CSO in ExpreS2ion and CEO of AdaptVac comments:
“These very promising results demonstrate the potential of the cVLP platform to be protective even after a single vaccine dose. In light of AdaptVac’s focus on COVID-19, this is an extremely encouraging verification of the efficacy of the platform for respiratory viruses.”
Paper reference: Vaccines 2020, 8, 389; doi:10.3390/vaccines8030389
https://www.mdpi.com/2076-393X/8/3/389#abstract.
About AdaptVac
AdaptVac ApS s a joint venture between ExpreS2ion Biotechnologies ApS and NextGen Vaccines ApS, owned by the inventors of the novel proprietary and ground-breaking capsid virus-like particle (cVLP) platform technology spun out from the University of Copenhagen. The Company aims to accelerate the development of highly efficient therapeutic and prophylactic vaccines within high value segments of oncology, infectious diseases and immunological disorders. Granting of the core patent in the U.S. has expanded AdaptVac’s patent protection to include the full pipeline of vaccines and immunotherapies in development.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telephone: +46 11 32 30 732
E-mail: ca@skmg.se
For further information about ExpreS2ion, please contact:
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com
About ExpreS2ion
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. Since 2017, ExpreS2ion develops novel VLP based vaccines through its joint venture AdaptVac ApS. For additional information, please visit www.expres2ionbio.com and www.adaptvac.com.
